SDC2 and diabetic cardiomyopathy: Given the importance of cardiac inflammation in diabetic cardiomyopathy (32) and the immunomodulatory properties of MSCs (33), we next evaluated the impact of i.v. WT, CD362−, and CD362+ MSC application on cardiac immune cell presence.